Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7675734 | 0.86 | MCL1 (0.41) | HTR2CHTR2AMCL1BAZ2BEGLN1 | |
| SCHEMBL7673579 | 0.85 | HTR2A (0.38) | HTR2CHTR2AMCL1EGLN1PTGDR2 | |
| SCHEMBL6483800 | 0.81 | MEN1 (0.47) | PTGDR2 | |
| SCHEMBL6851580 | 0.80 | MCL1 (0.32) | HTR2CHTR2AMCL1 | |
| Maleic Acid SCHEMBL6484489 | 0.79 | HTR2C (0.54) | HTR2CHTR2AMCL1EGLN1 | |
| Fumaric Acid SCHEMBL6484495 | 0.79 | HTR2C (0.54) | HTR2CHTR2AMCL1EGLN1 | |
| SCHEMBL7673244 | 0.79 | MAPT (0.30) | HTR2CHTR2A | |
| SCHEMBL6850266 | 0.78 | HTR2C (0.65) | HTR2CHTR2A | |
| SCHEMBL7674690 | 0.78 | PTGDR (0.31) | PTGDR2PTGDR | |
| SCHEMBL7670341 | 0.76 | MCL1 (0.42) | HTR2CHTR2AMCL1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2C 24/4885HTR2A 43/4885MCL1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.